IP Library › Granted Patent US 10,588,916
Granted Patent B2
US 10,588,916 · App. 16/160,840 · Granted Mar 17, 2020

Technology to inhibit vascular changes that lead to vision loss in the eye

Inventors: Pam Tsuruda (Brisbane, CA); Jill Hopkins (Brisbane, CA); Harry Sweigard (Brisbane, CA); Yan Poon (Brisbane, CA); Jamie Dananberg (Brisbane, CA); Daniel Marquess (Brisbane, CA); Nathaniel David (Brisbane, CA)
Assignee: Unity Biotechnology, Inc.
A61K31/635A61P27/02A61K9/0019A61K9/0048A61K47/10A61K47/20A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,588,916
App. No.
16/160,840
Granted
Mar 17, 2020
Kind
B2
Abstract

This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

Claims (5)

1. A method of inhibiting vaso-obliteration that leads to vision loss in an eye of a subject in need thereof, comprising administering to the eye a pharmaceutical composition comprising an effective amount of a compound, wherein the compound is BM-1197.

2. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in inhibiting pathogenic angiogenesis in the eye.

3. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in inhibiting retinal neovascularization in the eye.

4. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in inhibiting retinal or choroidal vascular leakage in the eye.

5. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in promoting repair of functional vasculature in the eye.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2019
From: TSURUDA, PAM; HOPKINS, JILL; SWEIGARD, HARRY; POON, YAN; DANANBERG, JAMIE; MARQUESS, DANIEL; DAVID, NATHANIEL
To: UNITY BIOTECHNOLOGY, INC.
Reel/Frame 049933/0218 →
Priority Claims (1)
EP 18188799 · Aug 13, 2018 · regional
Continuity (3)
Continuation PCTUS2018046553 · Aug 13, 2018
Provisional Application 62579793 · Oct 31, 2017
Related Publication 20190151337A1 · May 23, 2019
Cited By (1)
US 12,221,433